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Critically Ill Hospitalized Patients Undergoing
Echocardiography With and Without an
Ultrasound Contrast Agent
Alex Exuzides, PHD,* Michael L. Main, MD,† Chris Colby, PHD,* Paul A. Grayburn, MD,‡
Steven B. Feinstein, MD,§ Jonathan H. Goldman, MD
San Francisco, California; Kansas City, Missouri; Dallas, Texas; and Chicago, Illinois
O B J E C T I V E S To compare acute mortality in critically ill hospitalized patients undergoing echo-
cardiography with and without an ultrasound contrast agent (UCA).
B A C KG ROUND Because of serious cardiopulmonary reactions reported immediately after admin-
istration of perﬂutren-containing UCAs, the FDA required a black box safety warning for this class of
agents, including perﬂutren protein-type A microspheres injectable suspension.
METHOD S This study used the largest hospital service-level database in the U.S. All adult patients
undergoing in-patient echocardiography between January 2003 and October 2005 were identiﬁed
(n  2,588,722, of which 22,499 received perﬂutren protein-type A microspheres injectable suspension). Of
the 22,499 contrast echocardiography patients, 2,900 had diagnoses meeting criteria for critical illness (heart
failure, acute myocardial infarction, arrhythmia, respiratory failure, pulmonary embolism, emphysema, and
pulmonary hypertension). To control for the differences between the contrast and noncontrast patients, we
used propensity score matching. Variables used in the construction of the propensity score included
comorbidities, demographic factors, hospital-speciﬁc factors, level of care, and mechanical ventilation status.
Patients receiving contrast echocardiography were matched to 4 control patients who received noncontrast
echocardiography. Conditional logistic regression was used to estimate mortality effects.
R E S U L T S There were 167 deaths in the study among critically ill patients, 38 of 2,900 from the
contrast group and 129 of 11,600 from the control group. The contrast agent was not associated with
an increase in same-day mortality (odds ratio: 1.18; 95% conﬁdence interval: 0.82 to 1.71; p  0.37).
Before matching, contrast patients showed greater morbidity than noncontrast patients (Deyo-Charlson
comorbidity score 2.45 vs. 2.25, p  0.0001). After propensity score matching, these differences were
signiﬁcantly reduced, showing that both groups were well balanced.
CONC L U S I O N S There is no increase in mortality in critically ill patients undergoing echocardi-
ography with the UCA compared with case-matched control patients. (J Am Coll Cardiol Img 2010;3:
578–85) © 2010 by the American College of Cardiology Foundation
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579n October 2007, the U.S. Food and Drug Admin-
istration (FDA) issued a new black box warning,
multiple new disease state contraindications, and a
mandated 30-min monitoring period after con-
rast agent injection for the perflutren-based ultra-
ound contrast agents (UCA) (Optison, perflutren
rotein type A microspheres for injectable suspen-
ion [GE Healthcare, Buckinghamshire, United
ingdom] and Definity, perflutren lipid micro-
phere injectable suspension [Lantheus Medical
maging, North Billerica, Massachusetts]) (1).
he actions of the FDA authorities appeared to
oincide with the post-marketing reports of 11
eaths after UCA administration and approxi-
ately 200 cases of serious nonfatal reactions.
hese self-reported events included deaths and
dverse events that were reported but not inde-
endently adjudicated. To place these events in
ontext, these reports occurred over a period of
pproximately 10 years after nearly 3.5 million
njections of these UCAs.
In July 2008, the FDA changed the contrain-
ications to warnings for both UCAs. The mod-
fication of label was preceded by a grassroots
dvocacy group of clinicians (2,3), the publications
f peer-reviewed data studies (4), and a realistic
nderstanding of the probable risk–benefit rela-
ionship for contrast-enhanced echocardiography in
atients (5–7,8).
Coincident with the modified labeling changes
nd before the convening of a Cardio-Renal
dvisory Panel on UCA safety, the FDA officials
nnounced that GE Healthcare and Lantheus
edical Imaging agreed to conduct 2 follow-up
afety programs (9) that included the following:
) a retrospective, observational study that would
se an administrative database to compare acute
ortality in critically ill hospitalized patients who
ad received UCA (similar in scope to a single-
ite published report [4]); and 2) a prospective,
ulmonary artery hemodynamic study in which
atients would receive intravenous injections of
CA during a diagnostic, cardiac catheterization.
he objective of the current study was to compare
ame-day in-hospital mortality in critically ill
atients undergoing echocardiography with the
ddition of UCA (Optison) with mortality in
ritically ill patients undergoing echocardiogra-
hy without the use of a UCA. The secondary
bjective of this study was to compare in-hospital
ortality on the same day as or the day after thechocardiography procedure. pE T H O D S
his was a retrospective case–control analysis of
ortality in critically ill patients undergoing echo-
ardiography in the presence of UCA (Optison)
ontrast compared with matched control patients.
he study design was prospectively approved by the
DA, and the study was performed in partial
ulfillment of the risk mitigation plan. The analysis
ataset was derived from Premier Perspective data-
ase (Premier, Inc., Charlotte, North Carolina).
remier uses a consistent and secure sample of over
00 hospitals in the U.S., with a 93% hospital
etention rate. This database is the largest hospital-
ased, service-level comparative database in the U.S.
t includes all billed items, including procedures,
edications, laboratory, and diagnostic and therapeu-
ic services (including drugs and devices). It also
ncludes all diagnoses for each patient. Detailed
ervice-level information was available for each hospi-
al day and included medication information
nd location within hospital. Data collected
ncluded patient demographics (age, sex, and
ace/ethnicity) along with the hospital’s
eaching status, urban/rural location, and
eographic region. The database was sub-
ected to quality/integrity checks to ensure a
igh level of data reliability. A propensity-
atching score matching approach was used
or selection of noncontrast control patients.
The design of this study fulfilled the
DA officials’ request for a retrospective
omparison of the mortality rate among
ritically ill patients requiring UCA-
nhanced echocardiography as compared with pa-
ients who did not receive UCA.
Differences in baseline and/or clinical character-
stics among patients receiving UCA were ac-
ounted for by using a comparator group, those
atients who did not receive UCA. This study
esign allowed for the control patients to be
atched to cases with a similar propensity score.
atient inclusion criteria. The population of interest
omprised hospitalized patients from the database
ho underwent at least 1 clinically indicated echo-
ardiogram during the period from January 1, 2003
o November 1, 2005, and who were at least 18
ears old.
The final analysis sample included the subset of
ospitalized patients who underwent echocardiog-
aphy with UCA or without UCA. Both groups
ncluded critically ill patients as defined by the
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580onditions: unstable heart failure (40.7% of cases),
cute myocardial infarction (38.2%), arrhythmia
5.1%), respiratory failure (13.4%), pulmonary em-
olism or emphysema (2.5%), and pulmonary hy-
ertension (0.2%) as the admitting diagnosis (Table
). Critical illness was defined using the Interna-
ional Classification of Diseases, Clinical Modifi-
ation, 9th edition (ICD-9-CM) codes.
Covariates included the available demographic
nd clinical variables for each patient listed in the
tudy population. Additionally, hospital-specific
diopulmonary Conditions
Description Distribution (%)
unstable congestive heart failure 40.7
ction or acute coronary syndrome 38.2
ythmias or high risk for arrhythmia due to
QT interval
5.1
ifest by signs and symptoms of hypoxemia 13.4
lmonary emboli, or other conditions that
ry hypertension
2.5
n 0.2
ial Covariates
Variables
on
tion
gh ED
V at any point in the hospital admission up to the same day as
phy
r than those patients receiving MV, at any point in the hospital
to the same day as echocardiography
ny point in the hospital admission up to the same day as
phy
eatment
i-inﬂammatory drug use
disease
ary disease
isease
, including leukemia and lymphoma
tumor
ders
disease
conditions
are unit; ED  emergency department; ICU  intensive care unit; MV ition.ariables included teaching status, urban/rural loca-
ion, and geographic region. Also included were
ariables that indicated anticoagulant and nonste-
oidal anti-inflammatory drug uses.
Individual patient baseline morbidity level was
ssessed using elements of the Deyo-modified
harlson comorbidity index (DM-CCI). The DM-
CI weighted patients by comorbid conditions to
ssess risk of mortality (10). The CCI was later
odified by Deyo et al. (11), who matched the
onditions to ICD-9-CM diagnosis codes. The
M-CCI method has been widely used as an
djustor to control for comorbidities in retrospec-
ive database analyses. Table 2 lists the initial
ovariates.
tatistical analysis. Propensity score matching was
sed to control for the differences in observable
ovariates and to reduce the selection bias in case–
ontrol studies (12). All analyses were performed
sing SAS 9.1.3 (SAS Institute, Inc., Cary, North
arolina).
The first step in the propensity score matching
as to model the choice between Optison and
oncontrast echocardiogram. Each of the variables
isted in Table 2 was included in a logistic regres-
ion, and no interaction terms were included in this
ropensity score model. Stepwise regression analy-
is was used to select the covariates with the best
redictive power. SAS PROC LOGISTIC with
he SELECTION  STEPWISE option was
sed; the default significance level was 0.05.
For each patient who received UCA, 4 matched
ontrol patients were assigned who showed similar
ropensity scores. This selection process utilized the
mallest difference between propensity scores
mong the contrast patients and the control popu-
ation. This method is described as the nearest
eighbor matching and was used to implement the
AS macro [greedy matching algorithm (13)]. This
atching algorithm performed up to 7 passes to
nd a match for each case. First, it searched for
ontrol patients with propensity scores within a
olerance of 0.0000001 and progressively relaxes the
olerance by 1 digit until reaching a value of 0.1.
Of note, selection of more than 4 control patients
er case did not result in a substantial gain in
tatistical efficacy (14). This process created clusters
f closely matched individual patients and well-
alanced case and control groups. To compare
n-hospital mortality, a conditional logistic regres-
ion model was used and a clustering variableTable 1. Unstable Car
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581ontrast case (15). The adjusted odds ratio of
ortality for the 2 groups was estimated along with
95% confidence interval (CI). The propensity
core matching adjusted for baseline imbalances
etween the 2 groups. No covariates were used in
he conditional logistic regression model for the
rimary, secondary, or exploratory analysis.
For the secondary analysis objective, the multi-
ariable analysis was repeated as described above to
ompare in-hospital mortality on the same day as or
ay after echocardiography.
There were no patients with missing data once all
nclusion and exclusion criteria had been applied.
here was no imputation for missing values.
Table 3. Descriptive Statistics: Contrast Versus Noncontrast Pat
Variables
Cont
Mean or %
Age 65.64
Sex (% female) 38.62%
Race (% white) 73.45%
Geographic region: Midwest 30.66%
Geographic region: Northeast 15.76%
Geographic region: South 50.97%
Geographic region: West 2.62%
Urban/rural location (% urban) 91.83%
Hospital type (% teaching) 63.59%
Admission through ER 57.38%
MV: receiving MV at any point in the hospital
admission up to the same day as
echocardiography
17.00%
ICU: in ICU, other than those patients receiving MV,
at any point in the hospital admission up to the
same day as echocardiography
22.14%
CCU: in CCU at any point in the hospital admission
up to the same day as echocardiography
15.00%
Anticoagulant treatment 95.90%
Nonsteroidal anti-inﬂammatory drug use 11.07%
Deyo-modiﬁed CCI (DM-CCI) 2.45
Cerebrovascular disease (part of DM-CCI) 9.41%
Chronic pulmonary disease (part of DM-CCI) 34.93%
Rheumatologic disease (part of DM-CCI) 1.55%
Liver disease (part of DM-CCI) 1.03%
Diabetes type 1 (part of DM-CCI) 35.24%
Diabetes type 2 (part of DM-CCI) 17.72%
Renal disease (part of DM-CCI) 9.10%
Malignancy (part of DM-CCI) 5.72%
Severe liver disease (part of DM-CCI) 2.07%
Metastatic cancer (part of DM-CCI) 4.76%
CAD comorbidity 61.59%
Musculoskeletal comorbidity 2.17%
Depression comorbidity 5.86%
*p Value using the Wilcoxon test for continuous variables and the Mantel-Haen
CAD  coronary artery disease; DM-CCI  Deyo-modiﬁed Charlson comorbidity inE S U L T S
escriptive statistics. There were 208,878 noncon-
rast patients and 2,900 contrast patients who met
ll of the eligibility criteria for the study. The
ifferences in covariates before the propensity score
atching are shown in Table 3. Of the 29 covari-
tes, 25 show statistically significant differences
etween the contrast patients and the noncontrast
atients (with 18 covariates with a value of p 
.0001, including the DM-CCI score).
These differences included potentially important
onfounding variables such as chronic obstructive
ulmonary disease, coronary artery disease, renal
s
Patients (N  2,900) Noncontrast Patients (N  208,
Median SD IQR Mean or % Median SD
67 13.26 19 69.39 72 14.41
49.80%
65.65%
19.20%
19.43%
49.62%
11.75%
89.89%
45.96%
70.54%
11.02%
17.20%
13.00%
92.26%
8.77%
2 1.53 2 2.25 2 1.56
7.55%
31.54%
2.25%
0.91%
29.17%
11.76%
6.30% NA
7.86%
1.13%
8.38%
54.85%
2.13%
6.65%
test for categorical variables.ient
rast 878)
p Value*IQR
22 0.0001
0.0001
0.0001
0.0001
0.0001
0.1509
0.0001
0.0006
0.0001
0.0001
0.0001
0.0001
0.0015
0.0001
0.0001
2 0.0001
0.0002
0.0001
0.0115
0.4894
0.0001
0.0001
0.0001
0.0032
0.0065
0.0058
0.0001
0.8863
0.0908
szel
dex; IQR  interquartile range; NA  not applicable; other abbreviations as in Table 2.
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582isease, and diabetes (both type 1 and type 2).
here were differences in the level of care between
he noncontrast and contrast patients. Specifically,
7.0% of contrast patients were treated with me-
hanical ventilation, compared with 11.0% of the
oncontrast patients (p  0.0001).
After matching on propensity score, the observ-
ble difference between the 2 groups was reduced
Table 4). Only 5 covariates showed statistically
ignificant differences between the contrast patients
nd the matched control patients: northeast hospi-
al region (p  0.0032), south hospital region (p 
.0155), anticoagulation therapy (p  0.0138),
onsteroidal anti-inflammatory use drug (p 
.0057), and renal disease (p  0.0439). For con-
tatistics: Matched Control Patients
ariables
Contrast Patients (N  2,90
Mean or % Median SD
65.64 67 13.26
38.62%
73.45%
dwest 30.66%
rtheast 15.76%
uth 50.97%
st 2.62%
urban) 91.83%
ing) 63.59%
57.38%
y point in the hospital
same day as
17.00%
those patients receiving MV,
hospital admission up to the
rdiography
22.14%
int in the hospital admission
as echocardiography
15.00%
nt 95.90%
matory drug use 11.07%
-CCI) 2.45 2 1.53
e (part of DM-CCI) 9.41%
ease (part of DM-CCI) 34.93%
(part of DM-CCI) 1.55%
M-CCI) 1.03%
f DM-CCI) 35.24%
f DM-CCI) 17.72%
DM-CCI) 9.10%
-CCI) 5.72%
art of DM-CCI) 2.07%
of DM-CCI) 4.76%
61.59%
bidity 2.17%
y 5.86%
on test for continuous variables and the Mantel-Haenszel test for categorical var
isease; DM-CCI  Deyo-modiﬁed Charlson comorbidity index; IQR  interquartile ranrast patients, 17.0% were treated with mechanical
entilation, compared with 17.1% of the matched
ontrol patients (p 0.8860). The overall similarity
f the 2 groups and the similarity in the clinically
mportant predictors, such as DM-CCI and me-
hanical ventilation status, indicates that the 2
roups were well balanced (for additional informa-
ion on propensity score model results, please see
he Online Appendix).
The final set of variables selected by the step-
ise regression is shown in Table 5. Results for
he primary and secondary analyses are shown in
able 6. There were 167 same-day deaths in the
tudy, 38 from the contrast group and 129 from the
ontrol group. There were no significant differences
Noncontrast Patients (N  11,600)
p Value*IQR Mean or % Median SD IQR
19 66.00 67 13.43 19 0.2442
37.61% 0.3164
73.93% 0.5968
30.06% 0.5325
13.63% 0.0032
53.47% 0.0155
2.84% 0.5287
91.22% 0.3013
62.69% 0.3715
57.63% 0.8075
17.11% 0.8860
22.09% 0.9521
14.40% 0.4093
96.82% 0.0138
9.37% 0.0057
2 2.42 2 1.53 2 0.2887
8.62% 0.1771
35.15% 0.8278
2.00% 0.1147
1.12% 0.6910
36.53% 0.1982
16.48% 0.2802
7.48% 0.0439
5.03% 0.2954
1.53% 0.2362
6.05% 0.2884
62.45% 0.3916
1.76% 0.1382
5.11% 0.1057
s.Table 4. Descriptive S
V
0)
Age
Sex (% female)
Race (% white)
Geographic region: Mi
Geographic region: No
Geographic region: So
Geographic region: We
Urban/rural location (%
Hospital type (% teach
Admission through ER
MV: receiving MV at an
admission up to the
echocardiography
ICU: in ICU, other than
at any point in the
same day as echoca
CCU: in CCU at any po
up to the same day
Anticoagulant treatme
Nonsteroidal anti-inﬂam
Deyo-modiﬁed CCI (DM
Cerebrovascular diseas
Chronic pulmonary dis
Rheumatologic disease
Liver disease (part of D
Diabetes type 1 (part o
Diabetes type 2 (part o
Renal disease (part of
Malignancy (part of DM
Severe liver disease (p
Metastatic cancer (part
CAD comorbidity
Musculoskeletal comor
Depression comorbidit
*p Value using the Wilcox iable
ge; NA  not applicable; other abbreviations as in Table 2.
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583etween the contrast patients and the matched
ontrol patients for same-day all-cause mortality
adjusted odds ratio: 1.184; 95% CI: 0.820 to 1.709;
 0.3675). The C statistic was 0.706, indicating
hat the model had good discriminative power.
There were 267 same-day or next-day deaths in
he study, 62 from the contrast group and 205 from
he control group. There were no statistically sig-
ificant differences between the contrast patients
nd the matched control patients for same-day or
ext-day all-cause mortality (adjusted odds ratio:
.222; 95% CI: 0.913 to 1.637; p  0.1780).
The same methodology was used to explore the
ffects of UCA on same-day mortality for 3 mutu-
lly exclusive subgroups: patients receiving mechan-
cal ventilation, intensive care unit (ICU) patients
ithout mechanical ventilation, and coronary care
nit (CCU) patients without mechanical ventila-
ion. These results are shown in Table 7. None of
he subgroups showed a statistically significant dif-
erence in same-day mortality.
There were 108 same-day deaths in the mechanical
entilation subgroup, with 22 in the contrast group
nd 86 in the control group. The adjusted odds ratio
as 0.832 (95% CI: 0.488 to 1.420; p  0.5120).
There were 30 same-day deaths in the ICU
ubgroup, with 9 in the contrast group and 21 in the
ontrol group. The adjusted odds ratio was 2.168
95% CI: 0.892 to 5.272; p  0.0878). There were
1 same-day deaths in the CCU subgroup, with 3
n the contrast group and 8 in the control group.
he adjusted odds ratio was 1.42 (95% CI: 0.376 to
.361; p  0.6052).
I S C U S S I O N
n October 2007, the FDA mandated significant
roduct labeling changes for UCA after several
nvestigator-reported deaths and approximately 200
serious, non-fatal reactions” that were temporally
elated, although not adjudicated and, therefore,
ot clearly causally attributable to UCA adminis-
ration (1). In July 2008, subsequent to publication
f new safety data in hospitalized patients under-
oing echocardiography with and without a UCA
4), physician advocacy (2,3), and an enhanced
ppreciation of UCA efficacy (5–7), the FDA offi-
ials again modified the product labels to reflect the
afety profile of available UCA (8). Conditional and
onsistent with the labeling revisions, industrial
ouses preparing UCA developed a risk mitigation
lan to further define the safety profile of UCA (9).
art of this plan included a retrospective observa-ional study using an administrative database toompare acute mortality in critically ill hospitalized
atients undergoing echocardiography with and
ithout a UCA.
Two similarly designed study results were recently
eported. The first retrospective study, Kusnetzky et
l. (4), compared acute mortality in hospitalized pa-
ients undergoing echocardiography with UCA
Definity) (n  6,196) to those who did not receive
CA (n  12,475). Those patients who received
ontrast showed higher clinical acuity, and corre-
pondingly, more comorbidity than patients undergo-
ng unenhanced echocardiography. Although propor-
ionally more critically ill patients were housed in the
ontrast group, there was no increase in 24-h mortality
n patients receiving the UCA (mortality rate 0.42% in
he contrast arm and 0.37% in the unenhanced echo-
ardiography arm, p  0.60).
In a second retrospective study that used the
remier Perspective database, Main et al. (16)
valuated the 1-day mortality in 4,300,966 hospi-
alized patients who underwent echocardiography
Tables 5. Covariates Used in Conditional Logistic Regression
Effect DF Wald Chi-S
Sex (% female) 1 64.368
Admission through ER 1 119.789
Care location (MV/ICU/CCU/other) 3 136.953
Age 7 161.624
Region 3 256.828
Anticoagulant treatment 1 16.294
Nonsteroidal anti-inﬂammatory drug use 1 6.467
Hospital type (teaching/nonteaching) 1 152.667
Race (white/nonwhite) 1 68.142
Cerebrovascular disease (part of DM-CCI) 1 7.657
Chronic pulmonary disease (part of DM-CCI) 1 7.610
Diabetes type 1 (part of DM-CCI) 1 71.209
Diabetes type 2 (part of DM-CCI) 1 52.568
Renal disease (part of DM-CCI) 1 15.108
Malignancy (part of DM-CCI) 1 6.313
Severe liver disease (part of DM-CCI) 1 3.886
CAD comorbidity 1 5.609
Depression comorbidity 1 4.354
Abbreviations as in Table 3.
Table 6. Primary and Secondary Results
Odds
Ratio
95% Co
Inte
Lower
Optison treatment, primary outcome:
same-day mortality (167 events)
1.184 0.82
Optison treatment, secondary outcome: 1.222 0.913quare p Value
9 0.0001
2 0.0001
8 0.0001
6 0.0001
2 0.0001
0.0001
5 0.011
8 0.0001
6 0.0001
2 0.0057
3 0.0058
1 0.0001
0.0001
4 0.0001
5 0.012
1 0.0487
9 0.0179
1 0.0369nﬁdence
rvals
p ValueUpper
1.709 0.3675
1.637 0.178
same-day or next-day mortality (267 events)
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584ith (n  58,254) or without (n  4,242,712)
CA (Definity). Crude mortality was similar in
oth groups (contrast mortality at 1 day  1.06%
s. 1.08% for unenhanced studies, p  0.613).
ultivariate regression analysis revealed that pa-
ients who received contrast were 24% less likely to
ie within 1 day as compared with patients who
nderwent unenhanced echocardiography (odds ra-
io: 0.75, 95% CI: 0.70 to 0.82).
The results of the present study are consistent
ith the reports from 2 previous publications, such
hat: 1) the design of the current analysis was
rospectively approved by FDA officials; 2) the
tudy included only critically ill hospitalized pa-
ients; and 3) propensity score matching was used to
ontrol for the baseline differences in covariates and
educed the potential selection bias that may occur
n case–control studies. Overall, there were no
ifferences identified in same-day or next-day mor-
ality in patients who received contrast at the time
f echocardiography versus patients who did not
eceive contrast. In addition, a subgroup analysis
ncluded patients who received mechanical ventila-
ion, ICU patients without mechanical ventilation,
nd CCU patients without mechanical ventilation.
he results revealed that there was no same-day or
alysis
Odds
Ratio
95% Conﬁdence
Intervals
p ValueLower Upper
subgroup, primary
mortality (108 events)
0.832 0.488 1.42 0.5012black box warning on ultrasound con- graphy clarifies unrate the established safety experience for UCA as
eflected in the published literature for UCA. Of
ote, the recently established post-marketing safety
ecord that began in 2008 now lists over 260,000
njections of either of the 2 available UCA (4,16–22).
This study has several limitations. First, the
esign is observational and treatment selection was
onrandom. Table 3 shows significant baseline
ifferences between the contrast group and the
oncontrast group. These differences were reduced
fter using a propensity-matching score. Second,
he cause of death was not available, and only crude
ortality was reported. Third, the discrete time of
eath was not available in the Premier database
only the day of death was recorded). The primary
utcome in this study was all-cause, same-day
ortality; the secondary outcome was all-cause,
ame-day or next-day mortality. The dataset listed
ortality and procedures date, and did not include
specific time.
O N C L U S I O N S
here was no increase in short-term mortality in
atients who underwent contrast-enhanced echo-
ardiography in a large, propensity-matched popu-
ation of critically ill patients. These findings were
onfirmed in high-risk patient subsets that included
ndividuals residing in ICUs and patients who
equired mechanical ventilation.
eprint requests and correspondence: Dr. Michael L.
ain, Saint Luke’s Mid America Heart Institute, 4330
ornall Road, Suite 2000, Kansas City, Missouri 64111.next-day mortality difference. These results corrob- E-mail: mmain@cc-pc.com.E F E R E N C E S
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